Brian Grow Email & Phone Number

Brian Grow Work

• 2017 - now Chief Commercial Officer @ Organogenesis
• now Organogenesis Names New Chief Commercial Officer and Chief Operating Officer @ Organogenesis
• now Brian Grow - Chief Commercial Officer at Organogenesis | The Org @ Organogenesis
• now Healing personalized. @ Organogenesis
• 2013 - 2016 Director of Sales (Commercial Operations) @ Organogenesis
• now About PuraPly Antimicrobial @ Organogenesis
• now PuraPlyTM Antimicrobial provides wounds with both polyhexamethylene biguanide and a purified collagen wound matrix. @ Organogenesis
• now See how PuraPly Antimicrobial utilizes a purified native collagen matrix to support healing and PHMB to create an effective antimicrobial barrier to resist microbial colonization within the matrix and reduce microbial penetration through the matrix.1... @ Organogenesis
• 2013 - 2013 Director, Commercial Operations- Central @ Organogenesis
• now Greater Boston @ Organogenesis
• now Current Product Portfolio: Apligraf®, Dermagraft®, TransCyte®, PuraPly™, PuraPly AM™, Affinity®, NuShield®,NuCel® and ReNu®. Apligraf® is supplied as a living, bi-layered skin substitute and is the only FDA-approved product indicated for healing both Dia @ Organogenesis
• now Careers at Organogenesis | Homepage @ Organogenesis
• 2012 - 2013 Assoc. Director, Marketing @ Organogenesis
  View Department
• 2011 - 2012 Affinity® Wound Covering: Fresh Amniotic Membrane Graft for Wounds @ Organogenesis
• now Rediscover healing that remains ahead of its time. @ Organogenesis
• 2006 - 2011 Unmatched Clinical Evidence In The Treatment Of VLUs and DFUs. Safety and Prescribing Info. Unsurpassed Coverage For Patients. Innovation That Remains Ahead Of Its Time. Unequaled Patient Access. Quality Customer Service. Reduce Healthcare Costs. Transform @ Organogenesis
• now Award-Winning Research from the University of Miami Evaluates Apligraf's ® Role in Reversing a Chronic Wound Environment @ Organogenesis
• 2004 - 2006 Award-winning research from a multidisciplinary team at the University of Miami provides new insight on what happens to a patient's genomic profile when Apligraf®, an FDA-approved, bioengineered living cell-based therapy from Organogenesis Inc., is applied @ Organogenesis
• now Apligraf® is First Wound Healing Therapy to Demonstrate Significant Change in Chronic Wound’s Genomic Profile @ Organogenesis
• now CANTON, Mass., Jan. 4, 2017 and PRNewswire and — Apligraf® – an FDA-approved, bioengineered living-cell therapy from Organogenesis Inc. – has become the first wound-healing therapy to demonstrate a… @ Organogenesis
• now Apligraf: A New Milestone in Skin Regrowth @ Organogenesis
• now St. Martin Hospital Wound Care Center reached a new milestone when Kerry Thibodeaux, M.D. and Wound Care Center Medical Director, recently applied the first Apligraf to a patient. Apligraf is a unique living-cell based product used to treat chronic... @ Organogenesis
• now Advanced Wound Care of St. Elizabeth Medical Center - Using Apligraf to Heal Diabetic Foot Ulcer @ Organogenesis
• 2003 - 2004 National - Sales @ Bristol Myers Squibb
• 2000 - 2003 Tissue Engineering Specialist @ Novartis
• 1999 - 2000 Senior Business Developer @ LightEdge Solutions
  View Department